Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing.  Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs.

June 2015 - Cranbury, New Jersey — Kenneth Bahrt, MD, FACR has joined Oncobiologics as its Chief Medical Officer.  A recognized expert in immunology, he brings over 30 years of clinical and pharmaceutical industry experience in both small molecule and protein therapeutics.    Oncobiologics Founder

Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing monoclonal antibody (mAb) biosimilars,has completed the construction of its GMP commercial launch manufacturing facility at its headquarters in Cranbury, New Jersey.

Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study.  This study is

Cranbury, NJ – February 12, 2015 — Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars,announced today that ONS-3010, its adalimumab (Humira®) biosimilar candidate met the primary endpoints in its first clinical study.

Cranbury, NJ  -- October 7, 2014 – Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors.

July 16, 2014:  Cranbury, NJ  Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc, a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.

Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market.  The scope of the agreement includes exclusive

Cranbury, NJ – June 12, 2014 — Oncobiologics, Inc. announced today that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira®. After reviewing Oncobiologics’ Clinical Trial

Mumbai, India and New Jersey, USA – June 2, 2014 — Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products.  Under the